Social Contribution Through the Foundation for the Promotion of Medical Technology
First written in FY2016. 2 of 5 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2018.
No other company in this theme has enough history to compare yet.
- FY2018DroppedAnnual reportThe current year's CSR and share-related disclosures contain no reference to support for social contribution activities through the disposal of treasury shares to the Fukuda Foundation for Medical Technology.
- FY2017-Q3AdvancedAnnual report
「Pursuant to a resolution of the Board of Directors dated 13 May 2016, the Company disposed of 150,000 treasury shares through a third-party allotment dated 3 October 2016, with SMBC Trust Bank, Ltd. (Fukuda Foundation for Medical Technology Trust Account) as the allottee.」
The disposal of 150,000 treasury shares to provide funding for the activities of the Fukuda Foundation for Medical Technology was completed on 3 October 2016. - FY2017-Q2RestatedAnnual report
「The treasury shares will be disposed of to the trust established to provide funding for the Foundation’s social contribution activities.」
The purpose of supporting funding for activities such as research grants and international exchange grants through the disposal of treasury shares to the Fukuda Foundation for Medical Technology has been reiterated. - FY2017-Q1AdvancedAnnual report
「At a meeting of the Board of Directors held on 13 May 2016, the Company resolved to dispose of treasury shares through a third-party allotment to support the social contribution activities of the Fukuda Foundation for Medical Technology (the “Foundation”). The disposal of treasury shares was approved at the 69th Annual General Meeting of Shareholders held on 29 June 2016.」
The third-party allotment of treasury shares to support the Foundation progressed through Board approval and shareholder approval. The number of shares to be disposed of was 150,000, with the disposal date set as 3 October 2016. - FY2016First statedAnnual report
「The Foundation conducts public-interest activities, including grants and support for research and development in medical technology using ME and support for international exchange. We believe that carrying out these activities in a stable and continuous manner will help realize our corporate philosophy of contributing to the advancement of medicine.」
The Company plans to provide funding for activities such as medical technology research grants and international exchange support through the disposal of treasury shares to the Foundation.